Compare SPPL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | ATNM |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 33.9M |
| IPO Year | 2022 | 2013 |
| Metric | SPPL | ATNM |
|---|---|---|
| Price | $3.53 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 1.8M | 105.6K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.50 | $0.95 |
| 52 Week High | $7.00 | $1.89 |
| Indicator | SPPL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 36.37 |
| Support Level | $3.49 | $0.99 |
| Resistance Level | $4.60 | $1.27 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 70.32 | 0.10 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software (Facilities management software). The majority of its revenue is generated from the Robots segment. The company has expanded its operations into Australia /New Zealand and may also enter or expand in other geographic markets such as Canada, Hong Kong, Japan, the Middle East, the United Kingdom, Europe and the United States.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.